Athersys (Athersys) PensionAndRetirementBenefit : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Athersys PensionAndRetirementBenefit?

Athersys's PensionAndRetirementBenefit for the quarter that ended in Sep. 2023 was $0.00 Mil.

Athersys PensionAndRetirementBenefit Historical Data

The historical data trend for Athersys's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys PensionAndRetirementBenefit Chart

Athersys Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

PensionAndRetirementBenefit

Get a 7-Day Free Trial

Athersys Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
PensionAndRetirementBenefit	Get a 7-Day Free Trial															-	-	-	-	-

Athersys PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.

Athersys (Athersys) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (OTCPK:ATHXQ) » Definitions » PensionAndRetirementBenefit

Comparable Companies

Traded in Other Exchanges

N/A

Address

3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634

Website

https://www.athersys.com

Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Executives

Neema Mayhugh	director	3201 CARNEGIE AVE, CLEVELAND OH 44115
Joseph Patrick Nolan	director	100 PARK LANE, LAKE BLUFF IL 60044
Daniel A. Camardo	director, officer: Chief Executive Officer	ATHERSYS, INC., 3201 CARNEGIE AVE, CLEVELAND OH 44115
Maia Hansen	officer: Chief Operating Officer	16430 N. SCOTTSDALE ROAD, SCOTTSDALE AZ 85254
Kasey Rosado	officer: Interim, CFO	485 LEXINGTON AVE 10TH FLOOR, NEW YORK NY 10017
Ismail Kola	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
William Jr Lehmann	officer: President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
John J Harrington	director, officer: Chief Scientific Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Laura K Campbell	officer: Vice President	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Katherine Bach Kalin	director	3201 CARNEGIE AVENUE, CLEVELAND OH 44115
Baiju R. Shah	director	ONE INVACARE WAY, ELYRIA OH 44035
Jane Wasman	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Kenneth H Traub	director
Tadahisa Kagimoto	director, 10 percent owner	HEALIOS K.K., WORLD TRADE CENTER BLDG., 15F, 2-4-1 HAMAMATSUCHO, MINATO-KU, TOKYO M0 1056115